Extranodal NK/T-cell lymphoma (ENKTCL) is a relatively rare group of highly aggressive non-Hodgkin's lymphoma (NHL). The disease has rapid clinical progress, high degree of malignancy and poor prognosis. Traditional chemoradiotherapy regimens have not shown good efficacy. In recent years, the immunotherapy of tumors has developed rapidly. At present, it has shown strong therapeutic activity in the treatment of various solid tumors such as non-small cell lung cancer, prostate cancer, melanoma and kidney cancer. Multiple tumor immunotherapy drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. This article reviews recent novel immunotherapeutic regimens of ENKTCL, hoping to change the treatment modality of this malignant disease.
结外NK/T细胞淋巴瘤（ENKTCL）是一组比较少见的高度侵袭性的非霍奇金淋巴瘤。该病临床进展迅速、恶性程度高、预后较差，传统的放化疗方案并没有显示出良好的疗效。近几年来，肿瘤的免疫治疗迅猛发展，目前已在多种实体肿瘤如非小细胞肺癌、前列腺癌、黑色素瘤、肾癌的治疗中展示出了强大的治疗活性，多个肿瘤免疫治疗药物已经获得美国食品药品监督管理局批准上市并应用于临床。本文综述了近年来ENKTCL的新型免疫治疗方案，希望能够改变这种恶性疾病的治疗模式。.
Keywords: CD30; CD38; CTLA-4; EBV-associated antigen; Immunotherapy; Lymphoma, extranodal NK-T-cell; PD1/PDL1.